IL5 and COVID-19: We found that, while the EPs from HC inhibit IL-5 and IL-10 production, the EPs from COVID-19 patients failed in downregulating these two cytokines, suggesting that the composition of the EPs isolated from COVID-19 patients was supporting the ILC2 activation status (Figures 7A, B).